Advanced search

Online first
Review paper
Published online: 2024-11-18

open access

View PDF Download PDF file
Page views 27
Article views/downloads 7
Get Citation

Connect on Social Media

Connect on Social Media

Targeted nanodelivery systems for personalized cancer therapy

Szymon Roszkowski1, Zofia Durczynska2, Sylwia Szablewska2

Abstract

Conventional cancer therapies such as chemotherapy face challenges such as poor tumor targeting, systemic toxicity, and drug resistance. Nanotechnology offers solutions through advanced drug delivery systems that preferentially accumulate in tumors while avoiding healthy tissues. Recent innovations have enabled the optimization of engineered nanocarriers for extended circulation and tumor localization via both passive and active targeting mechanisms. Passive accumulation exploits the leaky vasculature of tumors, whereas active strategies use ligands to selectively bind cancer cell receptors. Multifunctional nanoparticles also allow the combination of imaging, multiple therapeutic modalities and on-demand drug release within a single platform. Overall, precisely tailored nanotherapeutics that leverage unique pathophysiological traits of malignancies provide opportunities to overcome the limitations of traditional treatment regimens. This emerging field promises more effective and personalized nanomedicine approaches to detect and treat cancer.

The key aspects highlighted in this review include the biological barriers associated with nanoparticles, rational design principles to optimize nanocarrier pharmacokinetics and tumor uptake, passive and active targeting strategies, multifunctionality, and reversal of multidrug resistance.

 

Keywords: nanotherapydrug deliverycancer targetingtumor microenvironmentpersonalized medicine

Article available in PDF format

View PDF Download PDF file

References

  1. Minelli C, Lowe SB, Stevens MM. Engineering nanocomposite materials for cancer therapy. Small. 2010; 6(21): 2336–2357.
    CrossRefPubMed
  2. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9): 941–951.
    CrossRefPubMed
  3. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2): 271–284.
    CrossRefPubMed
  4. Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4): 505–515.
    CrossRefPubMed
  5. Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73(5): 1524–1535.
    CrossRefPubMed
  6. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2(12): 751–760.
    CrossRefPubMed
  7. Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016; 244(Pt A): 108–121.
    CrossRefPubMed
  8. Jones DS, Silverman AP, Cochran JR. Developing therapeutic proteins by engineering ligand-receptor interactions. Trends Biotechnol. 2008; 26(9): 498–505.
    CrossRefPubMed
  9. Qian ZM, Li H, Sun H, et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002; 54(4): 561–587.
    CrossRefPubMed
  10. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103(16): 6315–6320.
    CrossRefPubMed
  11. Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014; 66: 2–25.
    CrossRefPubMed
  12. Shi J, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1): 20–37.
    CrossRefPubMed
  13. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189–207.
    CrossRefPubMed
  14. Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6(12): 815–823.
    CrossRefPubMed
  15. Gaumet M, Vargas A, Gurny R, et al. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008; 69(1): 1–9.
    CrossRefPubMed
  16. Nguyen PV, Hervé-Aubert K, Chourpa I, et al. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis. Int J Pharm. 2021; 609: 121134.
    CrossRefPubMed
  17. Talekar M, Kendall J, Denny W, et al. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anticancer Drugs. 2011; 22(10): 949–962.
    CrossRefPubMed
  18. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002; 235(1-2): 179–192.
    CrossRefPubMed
  19. Yuan H, Guo H, Luan X, et al. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer. Mol Pharm. 2020; 17(7): 2275–2286.
    CrossRefPubMed
  20. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol. 2005; 1(6): 755–762.
    CrossRefPubMed
  21. Montané X, Bajek A, Roszkowski K, et al. Encapsulation for Cancer Therapy. Molecules. 2020; 25(7).
    CrossRefPubMed
  22. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010; 62(11): 1052–1063.
    CrossRefPubMed
  23. Bae Y, Nishiyama N, Fukushima S, et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem. 2005; 16(1): 122–130.
    CrossRefPubMed
  24. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004; 303(5665): 1818–1822.
    CrossRefPubMed
  25. Camorani S, Tortorella S, Agnello L, et al. Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells. Pharmaceutics. 2022; 14(10).
    CrossRefPubMed
  26. Eljack S, David S, Chourpa I, et al. Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. Pharmaceuticals (Basel). 2022; 15(12).
    CrossRefPubMed
  27. Yang T, Han H, Chen Y, et al. Study the lipidoid nanoparticle mediated genome editing protein delivery using 3D intestinal tissue model. Bioact Mater. 2021; 6(11): 3671–3677.
    CrossRefPubMed
  28. Richter F, Leer K, Martin L, et al. The impact of anionic polymers on gene delivery: how composition and assembly help evading the toxicity-efficiency dilemma. J Nanobiotechnology. 2021; 19(1): 292.
    CrossRefPubMed
  29. Terada T, Kulkarni JA, Huynh A, et al. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach. Langmuir. 2021; 37(3): 1120–1128.
    CrossRefPubMed
  30. Chelakkot C, Ghim J, Ryu SHo. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018; 50(8): 1–9.
    CrossRefPubMed
  31. Lin CH, Chen CH, Lin ZC, et al. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J Food Drug Anal. 2017; 25(2): 219–234.
    CrossRefPubMed
  32. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012; 64(6): 557–570.
    CrossRefPubMed
  33. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009; 61(2): 158–171.
    CrossRefPubMed
  34. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009; 29(1): 196–212.
    CrossRefPubMed
  35. Hashemi Goradel N, Ghiyami-Hour F, Jahangiri S, et al. Nanoparticles as new tools for inhibition of cancer angiogenesis. J Cell Physiol. 2018; 233(4): 2902–2910.
    CrossRefPubMed
  36. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004; 9 Suppl 5: 31–40.
    CrossRefPubMed
  37. Keereweer S, Van Driel PB, Snoeks TJA, et al. Optical image-guided cancer surgery: challenges and limitations. Clin Cancer Res. 2013; 19(14): 3745–3754.
    CrossRefPubMed
  38. Wong C, Stylianopoulos T, Cui J, et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A. 2011; 108(6): 2426–2431.
    CrossRefPubMed
  39. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011; 63(3): 131–135.
    CrossRefPubMed
  40. Irvine DJ, Hanson MC, Rakhra K, et al. Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev. 2015; 115(19): 11109–11146.
    CrossRefPubMed
  41. Cruz LJ, Rosalia RA, Kleinovink JW, et al. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release. 2014; 192: 209–218.
    CrossRefPubMed
  42. Stephan MT, Moon JJ, Um SHo, et al. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med. 2010; 16(9): 1035–1041.
    CrossRefPubMed
  43. Buschow SI, Lasonder E, van Deutekom HWM, et al. Dominant processes during human dendritic cell maturation revealed by integration of proteome and transcriptome at the pathway level. J Proteome Res. 2010; 9(4): 1727–1737.
    CrossRefPubMed
  44. Rosalia RA, Cruz LJ, van Duikeren S, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015; 40: 88–97.
    CrossRefPubMed
  45. Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev. 2020; 157: 142–160.
    CrossRefPubMed
  46. Nel A, Ruoslahti E, Meng H. New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics. ACS Nano. 2017; 11(10): 9567–9569.
    CrossRefPubMed
  47. Toy R, Peiris PM, Ghaghada KB, et al. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond). 2014; 9(1): 121–134.
    CrossRefPubMed
  48. Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014; 37(1): 4–15.
    CrossRefPubMed
  49. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008; 60(15): 1615–1626.
    CrossRefPubMed
  50. Jaracz S, Chen J, Kuznetsova LV, et al. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem. 2005; 13(17): 5043–5054.
    CrossRefPubMed
  51. Elias DR, Poloukhtine A, Popik V, et al. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine. 2013; 9(2): 194–201.
    CrossRefPubMed
  52. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008; 16(2): 108–123.
    CrossRefPubMed
  53. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle. J Nanobiotechnology. 2013; 11: 26.
    CrossRefPubMed
  54. Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010; 10(9): 3223–3230.
    CrossRefPubMed
  55. Dreaden EC, Austin LA, Mackey MA, et al. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv. 2012; 3(4): 457–478.
    CrossRefPubMed
  56. Cruz E, Kayser V. Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles. Cancers (Basel). 2019; 11(6).
    CrossRefPubMed
  57. Huang X, El-Sayed IH, Qian W, et al. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc. 2006; 128(6): 2115–2120.
    CrossRefPubMed
  58. Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008; 2(5): 889–896.
    CrossRefPubMed
  59. Chen L, Zhou X, Nie W, et al. Multifunctional Redox-Responsive Mesoporous Silica Nanoparticles for Efficient Targeting Drug Delivery and Magnetic Resonance Imaging. ACS Appl Mater Interfaces. 2016; 8(49): 33829–33841.
    CrossRefPubMed
  60. Huang G, Chen H, Dong Y, et al. Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy. Theranostics. 2013; 3(2): 116–126.
    CrossRefPubMed
  61. Nance E, Timbie K, Miller GW, et al. Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound. J Control Release. 2014; 189: 123–132.
    CrossRefPubMed
  62. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62(11): 1064–1079.
    CrossRefPubMed
  63. Lammers T, Aime S, Hennink WE, et al. Theranostic nanomedicine. Acc Chem Res. 2011; 44(10): 1029–1038.
    CrossRefPubMed
  64. Khatun Z, Nurunnabi Md, Nafiujjaman Md, et al. Photoluminescent graphene nanoparticles for cancer phototherapy and imaging. ACS Appl Mater Interfaces. 2014; 6(15): 12413–12421.
    CrossRefPubMed
  65. Robinson JT, Tabakman SM, Liang Y, et al. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J Am Chem Soc. 2011; 133(17): 6825–6831.
    CrossRefPubMed
  66. Yang K, Zhang S, Zhang G, et al. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010; 10(9): 3318–3323.
    CrossRefPubMed
  67. Mamaeva V, Sahlgren C, Lindén M. Mesoporous silica nanoparticles in medicine--recent advances. Adv Drug Deliv Rev. 2013; 65(5): 689–702.
    CrossRefPubMed
  68. Slowing II, Vivero-Escoto JL, Wu CW, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60(11): 1278–1288.
    CrossRefPubMed
  69. Hom C, Lu J, Liong M, et al. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small. 2010; 6(11): 1185–1190.
    CrossRefPubMed
  70. Choi KiY, Min KH, Yoon HY, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials. 2011; 32(7): 1880–1889.
    CrossRefPubMed
  71. Hossann M, Wang T, Wiggenhorn M, et al. Size of thermosensitive liposomes influences content release. J Control Release. 2010; 147(3): 436–443.
    CrossRefPubMed
  72. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004; 64(21): 7668–7672.
    CrossRefPubMed
  73. Wang AZ, Bagalkot V, Vasilliou CC, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008; 3(9): 1311–1315.
    CrossRefPubMed
  74. Sahay G, Querbes W, Alabi C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013; 31(7): 653–658.
    CrossRefPubMed
  75. Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8): 541–555.
    CrossRefPubMed
  76. Niculescu AG, Grumezescu AM. Novel Tumor-Targeting Nanoparticles for Cancer Treatment-A Review. Int J Mol Sci. 2022; 23(9).
    CrossRefPubMed
  77. Khan MdI, Hossain MI, Hossain MK, et al. Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review. ACS Appl Bio Mater. 2022; 5(3): 971–1012.
    CrossRefPubMed
  78. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1): 48–58.
    CrossRefPubMed
  79. Brigger I, Dubernet C, Couvreur P, et al. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int J Pharm. 2001; 214(1-2): 37–42.
    CrossRefPubMed
  80. Dai Q, Wilhelm S, Ding D, et al. Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors. ACS Nano. 2018; 12(8): 8423–8435.
    CrossRefPubMed
  81. Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88(3): 53–71.
    CrossRefPubMed
  82. Zhang D, Liu L, Wang J, et al. Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front Pharmacol. 2022; 13: 990505.
    CrossRefPubMed
  83. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001; 42(7): 1007–1017.
    PubMed
  84. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003; 22(47): 7496–7511.
    CrossRefPubMed
  85. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003; 22(47): 7468–7485.
    CrossRefPubMed
  86. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1): 48–58.
    CrossRefPubMed
  87. Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10(2): 147–156.
    CrossRefPubMed
  88. Sangtani A, Petryayeva E, Susumu K, et al. Nanoparticle-Peptide-Drug Bioconjugates for Unassisted Defeat of Multidrug Resistance in a Model Cancer Cell Line. Bioconjug Chem. 2019; 30(3): 525–530.
    CrossRefPubMed
  89. Huszthy PC, Giroglou T, Tsinkalovsky O, et al. Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One. 2009; 4(7): e6314.
    CrossRefPubMed
  90. Wang K, Kievit FM, Zhang M. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies. Pharmacol Res. 2016; 114: 56–66.
    CrossRefPubMed
  91. Tzeng SY, Patel KK, Wilson DR, et al. In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci U S A. 2020; 117(8): 4043–4052.
    CrossRefPubMed
  92. Varlamova EG, Goltyaev MV, Mal'tseva VN, et al. Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines. Int J Mol Sci. 2021; 22(15).
    CrossRefPubMed
  93. Mazumdar S, Chitkara D, Mittal A. Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers. Acta Pharm Sin B. 2021; 11(4): 903–924.
    CrossRefPubMed
  94. Bechet D, Couleaud P, Frochot C, et al. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008; 26(11): 612–621.
    CrossRefPubMed
  95. Allison RR, Sibata CH. Oncologic photodynamic therapy photosensitizers: a clinical review. Photodiagnosis Photodyn Ther. 2010; 7(2): 61–75.
    CrossRefPubMed
  96. Ricci-Júnior E, Marchetti JM, Ricci-Júnior E, et al. Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. Int J Pharm. 2006; 310(1-2): 187–195.
    CrossRefPubMed
  97. Master AM, Sen Gupta A. EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine (Lond). 2012; 7(12): 1895–1906.
    CrossRefPubMed
  98. Wong HoL, Rauth AM, Bendayan R, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006; 23(7): 1574–1585.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note